Jubilant Pharmova Peer Comparison

NSE: JUBLPHARMA | BSE: 530019

₹999.30

₹-29.50 (-2.87%)

As on 01-Oct-2026IST

Market cap

₹15,938 Cr

Revenue (TTM)

₹8,608 Cr

P/E Ratio

45.3

P/B Ratio

2.2

Div. Yield

0.5 %

Edit

	Jubilant Pharmova	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Market cap (₹ Cr)	15,938	33,904	26,327	27,051	26,160
Revenue (₹ Cr)	8,608	3,564	9,205	1,936	1,462
Net Profit (₹ Cr)	351.60	414.00	-371.81	288.22	387.35
Net Margin (%)	4.05	11.23	-3.93	14.79	26.01
RoE (%)	5.68	8.38	-3.85	29.77	25.18
Price to Earnings	45.27	82.89	--	93.86	67.73
Price-To-Book	2.24	6.73	3.29	20.15	15.16

Income Statement (₹ Cr)

	Jubilant Pharmova	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Operating Revenue	8,608.30	3,564.00	9,205.28	1,935.80	1,461.80
Total Income	8,682.20	3,686.00	9,449.59	1,948.58	1,489.25
Total Expenditure	7,390.10	2,792.00	8,195.15	1,485.56	919.25
EBITDA	1,218.20	772.00	1,010.13	450.24	542.56
Depreciation	469.60	226.00	857.51	50.83	37.68
EBIT	748.60	546.00	152.62	399.41	504.88
Interest	217.00	217.00	342.73	40.84	3.77
Other Income	73.90	122.00	244.31	12.78	27.45
Exceptional Items	-59.20	12.00	-216.88	0.00	0.00
Profit before Tax	546.30	463.00	-162.68	371.35	528.56
Provision for Tax	194.70	49.00	209.13	83.14	141.21
Profit after Tax	351.60	414.00	-371.81	288.22	387.35

	Jubilant Pharmova	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Shareholder's Funds	7,092.80	4,940.00	8,162.62	1,288.82	1,653.56
Minority Interest	0.70	-5.00	0.00	0.00	-1.13
Non-Current Liabilities	5,888.20	1,712.00	5,044.14	202.03	42.40
Current Liabilities	2,538.90	1,622.00	4,758.28	835.87	230.82
Total Liabilities	15,272.00	8,578.00	17,723.32	2,326.71	1,983.96

	Jubilant Pharmova	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Non-Current Assets	10,892.60	5,343.00	10,211.52	519.60	1,026.85
Current Assets	4,109.30	2,606.00	7,191.66	1,681.81	881.27
Total Assets	15,272.00	8,578.00	17,723.32	2,326.71	1,983.96
Total Debt*	3,219.50	2,125.00	5,495.48	259.37	26.49
Net Current Assets	1,570.40	984.00	2,433.38	845.94	650.46
Contingent Liabilities	419.40	768.26	95.72	19.09	17.25

	Jubilant Pharmova	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Cash From Operating Activities	1,226.80	390.00	1,652.60	205.05	292.17
Cash Flow from Investing Activities	-1,260.00	-241.00	-826.03	-409.72	-265.94
Cash from Financing Activities	94.90	-54.00	-38.98	283.07	4.10
Net Cash Inflow / Outflow	61.70	95.00	787.59	78.39	30.33

	Jubilant Pharmova	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
ROCE (%)	8.69	6.79	1.24	29.22	32.42
ROE (%)	5.68	8.38	-3.85	29.77	25.18
ROA (%)	2.49	4.94	-2.21	24.77	21.93
EBIT Margin (%)	8.70	15.32	1.66	20.63	34.54
Net Margin (%)	4.05	11.23	-3.93	14.79	26.01
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Jubilant Pharmova	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Revenue Growth (%)	16.27	18.37	0.78	46.65	40.90
EBIT Growth (%)	-10.43	252.26	-70.53	62.13	124.50
Net Profit Growth (%)	-23.16	377.85	-1,383.43	89.49	104.15
EPS Growth (%)	-20.22	1,001.33	-484.84	78.60	42.32
Book Value Growth (%)	13.36	13.47	0.33	144.31	26.03

	Jubilant Pharmova	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Price / Earnings	40.99	85.08	-84.14	92.42	67.73
Price / Book Value	2.24	6.73	3.29	20.15	15.16
Dividend Yield (%)	0.50	0.00	0.00	0.09	0.08
EV/EBITDA	14.69	45.81	30.16	59.89	47.85
Market Cap (₹ Cr)	12,899.62	19,071.62	18,108.89	12,753.19	20,944.75

	Jubilant Pharmova	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Debt to Equity	0.42	0.31	0.53	0.11	0.02
Short term debt to equity ratio	0.02	0.09	0.09	0.05	0.02
Current Ratio	1.62	1.61	1.51	2.01	3.82
Quick Ratio	1.13	1.06	0.87	1.14	2.82
Interest Coverage	3.52	3.13	0.53	10.09	141.16

	Jubilant Pharmova	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Debtors to sales (%)	12.43	16.50	23.44	26.28	24.80
Asset Turnover	0.61	0.43	0.55	1.66	0.83
Receivable days	40.92	58.75	78.20	40.13	88.98
Inventory Days	49.26	75.82	93.30	60.29	56.04
Payable days	154.52	186.21	226.14	232.47	99.95
Cash Conversion Cycle	-64.33	-51.64	-54.64	-132.04	45.07

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.